These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 29268035)

  • 41. Efficacy and safety of teneligliptin, a dipeptidyl peptidase-4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled phase III trial.
    Kim MK; Rhee EJ; Han KA; Woo AC; Lee MK; Ku BJ; Chung CH; Kim KA; Lee HW; Park IB; Park JY; Chul Jang HC; Park KS; Jang WI; Cha BY
    Diabetes Obes Metab; 2015 Mar; 17(3):309-12. PubMed ID: 25475929
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: A subanalysis of a post-marketing study (J-STEP/EL Study).
    Kaku K; Naito Y; Senda M; Kurihara Y; Gunji R; Kakiuchi S; Utsunomiya K
    J Diabetes Investig; 2020 Mar; 11(2):405-416. PubMed ID: 31390166
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A ProspectIve, OpeN-Label, Randomized Study Comparing EffIcacy and Safety of Teneligliptin VErsus Sitagliptin in Indian Patients with Inadequately Controlled Type 2 Diabetes Mellitus: INSITES Study.
    Mohan V; Ramu M; Poongothai S; Kasthuri S
    J Assoc Physicians India; 2019 Oct; 67(10):14-19. PubMed ID: 31571445
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus: Results of 24-month interim analysis of a long-term post-marketing study (J-STEP/LT).
    Utsunomiya K; Kakiuchi S; Senda M; Fujii S; Kurihara Y; Gunji R; Koshida R; Kameda H; Tamura M; Kaku K
    J Diabetes Investig; 2020 Jul; 11(4):906-916. PubMed ID: 32034997
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Teneligliptin, a Chemotype Prolyl-Thiazolidine-Based Novel Dipeptidyl Peptidase-4 Inhibitor with Insulin Sensitizing Properties.
    Kutoh E; Wada A; Terayama S
    Clin Drug Investig; 2016 Oct; 36(10):809-18. PubMed ID: 27352309
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of the administration of teneligliptin every day versus every other day in Japanese patients with type 2 diabetes: a randomized non-inferior test.
    Kamiko K; Aoki K; Kamiyama H; Taguri M; Shibata E; Ashiya Y; Minagawa F; Shinoda K; Nakajima S; Terauchi Y
    J Clin Pharmacol; 2015 Feb; 55(2):144-51. PubMed ID: 25159300
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance study.
    Kaku K; Yamamoto K; Fukushima Y; Lliev H; Yasui A
    Expert Opin Drug Saf; 2022 Oct; 21(10):1315-1328. PubMed ID: 35315729
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus treated in real-world clinical practice: Results of a 36-month post-marketing surveillance study (J-STEP/LT).
    Utsunomiya K; Koshida R; Kakiuchi S; Senda M; Fujii S; Kurihara Y; Gunji R; Kaku K
    J Diabetes Investig; 2021 Feb; 12(2):184-199. PubMed ID: 32597517
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety and effectiveness of empagliflozin and linagliptin fixed-dose combination therapy in Japanese patients with type 2 diabetes: final results of a one-year post-marketing surveillance study.
    Inagaki N; Nishimoto T; Nishiya Y; Nitta D
    Expert Opin Drug Saf; 2023 Feb; 22(2):153-163. PubMed ID: 35946927
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real-world practice: Results of 12-month interim analysis of a long-term post-marketing surveillance study (J-STEP/LT).
    Utsunomiya K; Senda M; Kakiuchi S; Kameda H; Tamura M; Kurihara Y; Gunji R; Fujii S; Kaku K
    J Diabetes Investig; 2020 Jan; 11(1):132-141. PubMed ID: 31197929
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial.
    Eto T; Inoue S; Kadowaki T
    Diabetes Obes Metab; 2012 Nov; 14(11):1040-6. PubMed ID: 22776014
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Multicenter prospective observational study of teneligliptin, a selective dipeptidyl peptidase-4 inhibitor, in patients with poorly controlled type 2 diabetes: Focus on glycemic control, hypotensive effect, and safety Chikushi Anti-Diabetes Mellitus Trial-Teneligliptin (CHAT-T).
    Takamiya Y; Okamura K; Shirai K; Okuda T; Kobayashi K; Urata H
    Clin Exp Hypertens; 2020; 42(3):197-204. PubMed ID: 30974980
    [No Abstract]   [Full Text] [Related]  

  • 53. Effectiveness and safety of insulin glargine 300 unit/mL in Japanese type 2 diabetes mellitus patients: a 12-month post-marketing surveillance study (X-STAR study).
    Odawara M; Matsuhisa M; Hirose T; Koshida R; Senda M; Tanaka Y; Terauchi Y
    Expert Opin Pharmacother; 2020 Oct; 21(14):1771-1780. PubMed ID: 32693663
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and efficacy of vildagliptin: 52-week post-marketing surveillance of Japanese patients with type 2 diabetes in combination with other oral antidiabetics and insulin.
    Hayashi T; Murayama H; Shinfuku Y; Taniguchi T; Tsumiyama I; Oyama N
    Expert Opin Pharmacother; 2020 Jan; 21(1):121-130. PubMed ID: 31689132
    [No Abstract]   [Full Text] [Related]  

  • 55. Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: interim analysis from a post-marketing surveillance study.
    Kaku K; Chin R; Naito Y; Iliev H; Ikeda R; Ochiai K; Yasui A
    Expert Opin Drug Saf; 2020 Feb; 19(2):211-221. PubMed ID: 31769309
    [No Abstract]   [Full Text] [Related]  

  • 56. Efficacy and safety of teneligliptin in addition to insulin therapy in type 2 diabetes mellitus patients on hemodialysis evaluated by continuous glucose monitoring.
    Yajima T; Yajima K; Hayashi M; Takahashi H; Yasuda K
    Diabetes Res Clin Pract; 2016 Dec; 122():78-83. PubMed ID: 27810689
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Japanese study of tofogliflozin with type 2 diabetes mellitus patients in an observational study of the elderly (J-STEP/EL): A 12-week interim analysis.
    Utsunomiya K; Shimmoto N; Senda M; Kurihara Y; Gunji R; Kameda H; Tamura M; Mihara H; Kaku K
    J Diabetes Investig; 2016 Sep; 7(5):755-63. PubMed ID: 27181254
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of body mass index on the efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes mellitus: A subgroup analysis of 3-month interim results from the Specified Drug Use Results Survey of Ipragliflozin Treatment in Type 2 Diabetic Patients: Long-term Use study.
    Tobe K; Maegawa H; Tabuchi H; Nakamura I; Uno S
    J Diabetes Investig; 2019 Sep; 10(5):1262-1271. PubMed ID: 30719865
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of teneligliptin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.
    Ji L; Ma J; Lu W; Liu J; Zeng J; Yang J; Li W; Zhang X; Xiao X; Takayanagi G; Wang Y
    J Diabetes Investig; 2021 Apr; 12(4):537-545. PubMed ID: 32810383
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Teneligliptin, a DPP-4 Inhibitor, Decreases Plasma Levels of Inflammatory Chemokines During a Standard Meal Test in Patients With Type 2 Diabetes.
    Aso Y; Kase M; Sagara M; Sakurai S; Iijima T; Tomaru T; Jojima T; Usui I
    Am J Med Sci; 2020 Sep; 360(3):261-267. PubMed ID: 32540146
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.